Thomas Ichim, President and Chief Scientific Officer at Immorta Bio, shared on X:
“Finally! A CAR-T that works on solid tumors.
Nature paper… 32 out of 36 patients had regression of advanced cancer.
Target rglypican and tgf beta.”
Title: GPC3-specific dnTGFβRII-armoured CAR T cells for hepatocellular carcinoma
Authors: Qi Zhang, Qihan Fu, Yinan Shen, Wanyue Cao, Gaowei Jin, Yize Zhang, Jiangchao Wu, Cao Chen, Hongkan Wang, Xingyuan Xu, Ke Sun, Xing Xue, Attilio Bondanza, Daisy Cao, Nina Chu, Nick Durham, Mark Cobbold, Benedetto Farsaci, Maria Letizia Giardino Torchia, Yixin Hao, Yi Hong, Jiaqi Huang, Michael Humphries, Qijie Jian, Gordon Moody, John Stone, Lingyan Sun, Eric Tu, Fei Wang, Fuzhe Wang, Ye Yang, Yihong Yao, Andy Zou, Xueli Bai, Tingbo Liang
Read the full article.
